Researchers are comparing ALTO-100 and placebo to find out how the approaches affect depression symptoms in adults with bipolarity during a depressive episode.
Medication studyAges 18–70United Kingdom + United States
The study in practice
Understand this study
What is this study about?
Researchers are comparing ALTO-100 and placebo to find out how the approaches affect depression symptoms in adults with bipolarity during a depressive episode.
Who could participate?
This study is for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
Medication described in the protocol · Placebo comparator
Compensation
Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Study clarity
Things to check before joining
Study start dateStarted: October 2, 2024
Recruitment status
Recruiting
Enrollment listed in the registry
200
Sponsor
Alto Neuroscience
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, United Kingdom
Age range
From 18 Years to 70 Years
Official registry ID
NCT06656416
Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study Followed by Open-Label Treatment of ALTO-100 in Adults With Bipolar Disorder Currently Experiencing a Major Depressive Episode
Need help understanding this study?
Leave your email and we’ll get in touch to discuss your questions and possible next steps.
Recruitment & locations
Recruiting
Birmingham, United States · Chandler, United States · Phoenix, United States
57 more locations
Yuma, United States
Fayetteville, United States
Little Rock, United States
Chino, United States
Imperial, United States
Los Angeles, United States
Mather, United States
Oceanside, United States
Riverside, United States
Sacramento, United States
San Jose, United States
Colorado Springs, United States
Jacksonville, United States
Lauderhill, United States
Pinellas Park, United States
Tampa, United States
Atlanta, United States
Peachtree Corners, United States
Chicago, United States
Carmel, United States
West Lafayette, United States
Baltimore, United States
Bel Air, United States
Gaithersburg, United States
Towson, United States
Worcester, United States
Ann Arbor, United States
Grand Rapids, United States
Flowood, United States
Lincoln, United States
Las Vegas, United States
Toms River, United States
Albuquerque, United States
Amherst, United States
New York, United States
Cary, United States
Rose Hill, United States
Cincinnati, United States
North Canton, United States
Westlake, United States
Austin, United States
Beaumont, United States
Dallas, United States
Houston, United States
Plano, United States
Draper, United States
Fairfax, United States
Bellevue, United States
Derby, United Kingdom
Edinburgh, United Kingdom
Glasgow, United Kingdom
Liverpool, United Kingdom
London, United Kingdom
Newcastle upon Tyne, United Kingdom
Oxford, United Kingdom
Southampton, United Kingdom
York, United Kingdom
A listed location does not confirm current availability.
FAQ
Questions about this study
What is this study about?
Researchers are comparing ALTO-100 and placebo to find out how the approaches affect depression symptoms in adults with bipolarity during a depressive episode.
Who is behind this study?
The study sponsor is Alto Neuroscience.
Does this study involve medication?
Yes. The study involves medication, including ALTO-100 and Placebo.
Who can participate?
This study is for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.